Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06577987 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06577987 · ClinicalTrials.gov record · last posted 2026-08-26

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

StatusActive, Not Recruiting
PhasePhase 1
Started2024-08-14
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.

Protocol amendment history 1 change detected by DataLookout

2026-08-27
Enrollment closed, study ongoing
Trial Details
NCT Number NCT06577987
Lead Sponsor Circle Pharma
Conditions Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer, Lung Cancer, Triple Negative Breast Cancer, Breast Neoplasms, Neuroendocrine Tumors +2 more
Enrollment 220 participants
Start Date 2024-08-14
Primary Completion 2027-01-14 (estimated)
Study Completion 2027-03-14 (estimated)
Updated on ClinicalTrials.gov 2026-08-26